Eli Lilly, the global pharmaceutical giant, said the Therapeutic Goods Administration had approved the use of its Mounjaro ...

A popular weight-loss jab has been approved to treat a common sleep disorder in Australia, after a new ruling by the medicine ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

A new study to be presented at the SLEEP 2025 annual meeting found that sleep medicine professionals favor continuous ...

Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

A San Antonio weight loss clinic owner is encouraging consumers of the GLP-1 drug semaglutide not to panic now that the FDA ...

CI Insights From Zepbound to AD109, pharma innovation is reshaping Obstructive Sleep Apnea. Discover key players, C ...